(Corrects low end of pvs revenue forecast and U.S. pacemaker and defibrillator growth in 4th and 9th paragraphs)
By The Value Investor : St . Jude Medical (NYSE: STJ ) reported a solid set of third ..... For the past third quarter, St . Jude Medical posted sales of $1.37 billion ..... at $1.39 billion. While St . Jude posted modest topline sales
(Adds CFO, analyst comment, full-year forecast; updates shares)
By SA Transcripts : St . Jude Medical Inc. (NYSE: STJ ) Q3 2014 Results Earnings ..... Presentation Operator Welcome to the St . Jude Medical ’s Third Quarter 2014 Earnings ..... Chief Executive Officer of St . Jude Medical . Forward-looking statements
St . Jude Medical 's third-quarter results were largely ..... neuromodulation products, wide-moat St . Jude saw quarterly top-line growth of 3 ..... double-digit growth seen historically, St . Jude has been making steady progress recovering
St . Jude Medical (NYSE: STJ ) Q3 revenue growth by selected line item: Leaders : Intl Neuromodulation: +14.3%; International Atrial Fibrillation
St . Jude Medical (NYSE: STJ ) Q3 results : Revenues: $1,372M (+2.5%); International: $706M (+2.0%); U.S.: $666M (+3.1%); WW
Oct 15 (Reuters) - Heart device maker St . Jude Medical Inc reported a lower quarterly profit, as it took a $39 million charge related to impairment and restructuring, despite a rise in sales of its devices to treat abnormal heart rhythms.
St . Jude Medical (NYSE: STJ ): Q3 EPS of $0.97 beats by $0.01 . Revenue of $1.37B (+2.2% Y/Y) misses by $10M . Shares +0.15% PM. Press Release Post your comment!
ST . Jude Medical ( STJ +0.4% ) will report Q3 results on Wednesday, October 15 before the open. The conference call will begin at 6:30 am CT. Consensus view is EPS of $0.96 on revenues of $1.39B. Post your comment!